The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

<p dir="ltr">Intermittent fasting (IF) has recently gained popularity due to its emerging benefits in reducing weight and improving metabolic health. Concurrently, novel agents (NAs) like venetoclax and Bruton tyrosine kinase inhibitors (BTKIs) have revolutionized the treatment of ch...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Maria Benkhadra (19756941) (author)
مؤلفون آخرون:	Nuha Fituri (19756944) (author), Soha Aboukhalaf (19756947) (author), Rola Ghasoub (16555851) (author), Mervat Mattar (17430972) (author), Khalil Alfarsi (17430975) (author), Salem Alshemmari (19756950) (author), Mohamed A. Yassin (8361183) (author)
منشور في:	2024
الموضوعات:	Biomedical and clinical sciences Oncology and carcinogenesis chronic lymphocytic leukemia tumor lysis syndrome gastrointestinal bleeding intermittent fasting fluid-restricted intermittent fasting fluid-liberal intermittent fasting Bruton tyrosine kinase inhibitors (BTK) BCL2 inhibitors
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

مواد مشابهة